Hydroxylamines

Organic compounds that contain the (-NH2OH) radical.
DrugDrug NameDrug Indication
DB00176FluvoxamineIndicated predominantly for the management of depression and for Obsessive Compulsive Disorder (OCD) [FDA Label]. Has also been used in the management of bulimia nervosa [A250].
DB00551Acetohydroxamic AcidUsed, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections.
DB00733PralidoximeFor the treatment of poisoning due to those pesticides and chemicals of the organophosphate class which have anticholinesterase activity and in the control of overdosage by anticholinesterase drugs used in the treatment of myasthenia gravis.
DB00746DeferoxamineUsed to treat acute iron or aluminum toxicity (an excess of aluminum in the body) in certain patients. Also used in certain patients with anemia who must receive many blood transfusions.
DB00786MarimastatFor the treatment of various cancers
DB01630SC-74020Not Available
DB01747CoprogenNot Available
DB01924Benzhydroxamic AcidNot Available
DB02052Indirubin-3'-MonoximeNot Available
DB02071WAY-151693Not Available
DB02079Aminooxyacetic acidNot Available
DB02546VorinostatFor the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies.
DB02660FilaminastNot Available
DB03436GallichromeNot Available
DB03734XylarohydroxamateNot Available
DB04368Bb-3497Not Available
DB044964-Phospho-D-Erythronohydroxamic AcidNot Available
DB04857BrasofensineFor the treatment of Parkinson's Disease.
DB05015BelinostatBelinostat is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) with manageable safety profile. It is a potential alternative therapy for patients who did not experience adequate response to first-line drugs for PTCL. It can be used in patients with baseline thrombocytopenia [A19161].
DB06297LX-2931Investigated for use/treatment in rheumatoid arthritis, inflammatory disorders (unspecified), and autoimmune diseases.
DB06311DarapladibInvestigated for use/treatment in atherosclerosis.
DB06603PanobinostatPanobinostat is indicated in the treatment of multiple myeloma in combination with dexamethasone and bortezomib in patients who have received 2 previous treatment regimens including bortezomib and an immunomodulatory agent. This indication is approved by accelerated approval based on progression free survival as of February 23, 2015.
DB06680AsoprisnilInvestigated for use/treatment in uterine fibroids.
DB06713NorelgestrominNorelgestromin is used for contraception and menopausal hormonal therapy. Norelgestromin may potentially be used in breast cancer treatment due to its inhibitory effect on estrone sulfatase . They convert sulfated steroid precursors to estrogen during pregnancy.
DB08912DabrafenibTafinlar is a kinase inhibitor that was initially indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test [FDA label]. Tafinlar in combination with [DB08911] is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. The use in combination is based on the demonstration of durable response rate. Improvement in disease-related symptoms or overall survival has not been demonstrated for Tafinlar in combination with trametinib [FDA label]. In May 2018, Tafinlar (dabrafenib) and Mekinist ([DB08911]) have been approved in combination to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene [L2712].
DB08925AdrafinilUsed to relieve excessive sleepiness and inattention in elderly patients.
DB08955IbuproxamNot Available
DB09163Technetium Tc-99m exametazimeTechnetium Tc99m exametazime scintigraphy (with or without methylene blue stabilization) may be useful as an adjunct in the detection of altered regional cerebral perfusion in stroke. Tc99m exametazime without methylene blue stabilization is indicated for leukocyte labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease.
DB11781TosedostatNot Available
DB11912LanopepdenNot Available
DB12174CUDC-101Not Available
DB12259CG-200745Not Available
DB12376RicolinostatNot Available
DB12382R-306465Not Available
DB12392ResminostatNot Available
DB12565AbexinostatNot Available
DB12847PyroxamideNot Available
DB12948DidoxNot Available
DB12985QuisinostatNot Available
DB13346BufexamacIndicated for the treatment of various skin conditions, such as atopic eczema and other inflammatory dermatoses.
DrugDrug NameTargetType
DB00176FluvoxamineSodium-dependent serotonin transportertarget
DB00176FluvoxamineCytochrome P450 1A2enzyme
DB00176FluvoxamineCytochrome P450 2D6enzyme
DB00176FluvoxamineCytochrome P450 2C9enzyme
DB00176FluvoxamineCytochrome P450 2C19enzyme
DB00176FluvoxamineCytochrome P450 1A1enzyme
DB00176FluvoxamineCytochrome P450 3A4enzyme
DB00176FluvoxamineCytochrome P450 3A5enzyme
DB00176FluvoxamineCytochrome P450 3A7enzyme
DB00176FluvoxamineMultidrug resistance protein 1transporter
DB00176FluvoxamineCytochrome P450 2B6enzyme
DB00176FluvoxamineCytochrome P450 2E1enzyme
DB00176FluvoxaminePotassium voltage-gated channel subfamily H member 2target
DB00176FluvoxamineCytochrome P450 2C8enzyme
DB00176FluvoxamineBile salt export pumptransporter
DB00551Acetohydroxamic AcidUrease subunit alphatarget
DB00551Acetohydroxamic AcidMacrophage metalloelastasetarget
DB00733PralidoximeAcetylcholinesterasetarget
DB00733PralidoximeCholinesterasetarget
DB00746DeferoxamineXanthine dehydrogenase/oxidaseenzyme
DB00746DeferoxamineIrontarget
DB00746DeferoxamineAluminumtarget
DB00746DeferoxamineAmyloid beta A4 proteintarget
DB00786Marimastat72 kDa type IV collagenasetarget
DB00786MarimastatMatrix metalloproteinase-9target
DB00786MarimastatStromelysin-1target
DB00786MarimastatInterstitial collagenasetarget
DB00786MarimastatStromelysin-2target
DB00786MarimastatMatrilysintarget
DB00786MarimastatNeutrophil collagenasetarget
DB00786MarimastatStromelysin-3target
DB00786MarimastatMacrophage metalloelastasetarget
DB00786MarimastatCollagenase 3target
DB00786MarimastatMatrix metalloproteinase-14target
DB00786MarimastatMatrix metalloproteinase-15target
DB00786MarimastatMatrix metalloproteinase-16target
DB00786MarimastatMatrix metalloproteinase-17target
DB00786MarimastatMatrix metalloproteinase-19target
DB00786MarimastatMatrix metalloproteinase-20target
DB00786MarimastatMatrix metalloproteinase-21target
DB00786MarimastatMatrix metalloproteinase-23target
DB00786MarimastatMatrix metalloproteinase-24target
DB00786MarimastatMatrix metalloproteinase-25target
DB00786MarimastatMatrix metalloproteinase-26target
DB00786MarimastatMatrix metalloproteinase-27target
DB00786MarimastatMatrix metalloproteinase-28target
DB01630SC-7402072 kDa type IV collagenasetarget
DB01747CoprogenIron(3+)-hydroxamate-binding protein FhuDtarget
DB02052Indirubin-3'-MonoximeGlycogen synthase kinase-3 betatarget
DB02052Indirubin-3'-MonoximeCyclin-dependent kinase 5target
DB02052Indirubin-3'-MonoximeCyclin-dependent kinase 1target
DB02052Indirubin-3'-MonoximeCyclin-dependent kinase 5 activator 1target
DB02052Indirubin-3'-MonoximeCyclin-dependent kinase 2target
DB02052Indirubin-3'-MonoximeAryl hydrocarbon receptortarget
DB02071WAY-151693Collagenase 3target
DB02079Aminooxyacetic acidSerine--pyruvate aminotransferasetarget
DB02546VorinostatHistone deacetylase 1target
DB02546VorinostatHistone deacetylase 2target
DB02546VorinostatHistone deacetylase 3target
DB02546VorinostatHistone deacetylase 6target
DB02546VorinostatHistone deacetylase 8target
DB02546VorinostatAcetoin utilization proteintarget
DB02660FilaminastcAMP-specific 3',5'-cyclic phosphodiesterase 4Btarget
DB03436GallichromeIron(3+)-hydroxamate-binding protein FhuDtarget
DB03734XylarohydroxamateGlucarate dehydratasetarget
DB04368Bb-3497Peptide deformylasetarget
DB04368Bb-3497Peptide deformylase, mitochondrialtarget
DB044964-Phospho-D-Erythronohydroxamic AcidRibose-5-phosphate isomerase Btarget
DB04857BrasofensineD(2) dopamine receptortarget
DB05015BelinostatHistone deacetylasetarget
DB05015BelinostatCytochrome P450 1A2enzyme
DB05015BelinostatUDP-glucuronosyltransferase 1A1enzyme
DB05015BelinostatCytochrome P450 2C8enzyme
DB05015BelinostatCytochrome P450 2C9enzyme
DB05015BelinostatMultidrug resistance protein 1transporter
DB06311DarapladibCytosolic phospholipase A2target
DB06603PanobinostatCytochrome P450 2D6enzyme
DB06603PanobinostatCytochrome P450 3A4enzyme
DB06603PanobinostatMultidrug resistance protein 1transporter
DB06603PanobinostatHistone deacetylasetarget
DB06680AsoprisnilProgesterone receptortarget
DB06713NorelgestrominSteryl-sulfataseenzyme
DB06713NorelgestrominProgesterone receptortarget
DB06713NorelgestrominSerum albumintarget
DB06713NorelgestrominAndrogen receptortarget
DB06713NorelgestrominCytochrome P450 3A4enzyme
DB08912DabrafenibCytochrome P450 3A4enzyme
DB08912DabrafenibCytochrome P450 2C8enzyme
DB08912DabrafenibMultidrug resistance protein 1transporter
DB08912DabrafenibATP-binding cassette sub-family G member 2transporter
DB08912DabrafenibSolute carrier organic anion transporter family member 1B1transporter
DB08912DabrafenibSolute carrier organic anion transporter family member 1B3transporter
DB08912DabrafenibSolute carrier family 22 member 6transporter
DB08912DabrafenibSolute carrier family 22 member 8transporter
DB08912DabrafenibSerine/threonine-protein kinase B-raftarget
DB08912DabrafenibRAF proto-oncogene serine/threonine-protein kinasetarget
DB08912DabrafenibSerine/threonine-protein kinase SIK1target
DB08912DabrafenibSerine/threonine-protein kinase Nek11target
DB08912DabrafenibLIM domain kinase 1target
DB11781TosedostatPuromycin-sensitive aminopeptidasetarget
DB11781TosedostatLeukotriene A-4 hydrolasetarget
DB12565AbexinostatHistone deacetylase 1target
DB13346BufexamacProstaglandin G/H synthase 1target
DB13346BufexamacProstaglandin G/H synthase 2target
DB13346BufexamacHistone deacetylase 6target
DB13346BufexamacHistone deacetylase 10target